Guardant Health has entered into a strategic partnership with Trial Library, an AI‑powered platform that matches patients to clinical trials. The collaboration combines Guardant’s liquid‑biopsy diagnostics and real‑world data with Trial Library’s patient‑navigation technology to identify and enroll eligible patients in precision oncology studies across the United States.
The alliance leverages Trial Library’s network of more than 320 community‑based clinics and 1,500 providers, enabling Guardant to reach underserved and rural populations where trial enrollment rates are historically low. By integrating biomarker insights directly with trial opportunities, the partnership aims to streamline referral and enrollment processes for clinicians and patients alike.
Guardant’s platform has already tested over one million patients, and the company reported Q3 2025 revenue of $265.2 million, a 39% year‑over‑year increase. The firm has raised its full‑year 2025 revenue guidance to $965 million–$970 million, up from a prior range of $915 million–$925 million, reflecting confidence in continued demand for its diagnostic and data‑services offerings.
While the partnership’s financial terms remain undisclosed, the strategic fit is clear: Guardant can drive additional test orders and generate new service revenue by positioning its diagnostics as the gateway to clinical trials, while Trial Library gains access to Guardant’s extensive biomarker database and patient population. The collaboration is expected to accelerate trial enrollment, particularly in communities that have historically faced access barriers.
Helmy Eltoukhy, Guardant’s chairman and co‑CEO, said the partnership “bridges the gap between genomic discovery and equitable participation in lifesaving research.” Dr. Hala Borno, CEO of Trial Library, added that the alliance “transforms genomic data into expanded trial access, reshaping what equitable cancer care looks like.”
The partnership underscores a broader industry trend toward leveraging real‑world data and AI to improve clinical‑trial efficiency and patient access, positioning Guardant as a key player not only in diagnostics but also in the emerging clinical‑trial enablement space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.